降钙素原指导抗生素治疗对ICU感染和脓毒症患者临床结局的影响:随机试验的患者水平荟萃分析
该患者水平荟萃分析基于11项随机试验,纳入ICU感染且任何类型脓毒症患者,比较降钙素原指导抗生素治疗(降钙素原组)与当前标准治疗(对照组)。主要终点为30天死亡率,降钙素原组2252例死亡率为21.1%,对照组2230例为23.7%,调整OR 0.89(95%CI 0.8-0.99,p=0.03)。亚组分析显示该效应在符合脓毒症3定义、不同严重程度(SOFA评分、脓毒性休克或肾衰竭、需要血管加压药或通气支持)及不同感染类型中持续存在,交互作用均>0.05。降钙素原指导还促进更早停用抗生素,治疗 duration 9.3 vs 10.4天,调整系数-1.19天(95%CI -1.73至-0.66,p<0.001)。
要点
- 在ICU感染和脓毒症患者中,降钙素原指导抗生素治疗组30天死亡率为21.1%,对照组为23.7%,调整OR 0.89(95%CI 0.8-0.99,p=0.03)。
- 降钙素原指导缩短抗生素治疗 duration:9.3 vs 10.4天,调整系数-1.19天(95%CI -1.73至-0.66,p<0.001)。
- 死亡率获益在符合脓毒症3定义、不同严重程度(SOFA评分、脓毒性休克或肾衰竭、需要血管加压药或通气支持)及不同感染类型(呼吸道、泌尿道、腹部、皮肤或中枢神经系统)的亚组中持续存在,交互作用均>0.05。
- 该分析基于11项随机试验的个体患者数据,共纳入降钙素原组2252例和对照组2230例。
适用人群与场景
- ICU感染且任何类型脓毒症患者,来自11项随机试验的个体患者数据。
研究设计与关键结果
- 研究类型:基于11项随机试验的个体患者水平荟萃分析。
- 人群:ICU感染和脓毒症患者,降钙素原组2252例,对照组2230例。
- 干预与对照:降钙素原指导抗生素治疗 vs 当前标准治疗。
- 主要终点:30天死亡率,降钙素原组21.1% vs 对照组23.7%,调整OR 0.89(95%CI 0.8-0.99,p=0.03)。
- 关键次要终点:抗生素治疗 duration 降钙素原组9.3天 vs 对照组10.4天,调整系数-1.19天(95%CI -1.73至-0.66,p<0.001)。
- 亚组分析:死亡率效应在符合脓毒症3定义、不同严重程度(SOFA评分、脓毒性休克或肾衰竭、需要血管加压药或通气支持)及不同感染类型(呼吸道、泌尿道、腹部、皮肤或中枢神经系统)中持续存在,交互作用均>0.05。
证据类型、等级与局限
- 证据类型:患者水平荟萃分析,基于11项随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在ICU感染和脓毒症患者中,降钙素原指导抗生素治疗与30天死亡率降低相关(21.1% vs 23.7%,调整OR 0.89),并缩短抗生素治疗 duration(9.3 vs 10.4天,调整系数-1.19天)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The clinical utility of serum procalcitonin levels in guiding antibiotic treatment decisions in patients with sepsis remains unclear. This patient-level meta-analysis based on 11 randomized trials investigates the impact of procalcitonin-guided antibiotic therapy on mortality in intensive care unit (ICU) patients with infection, both overall and stratified according to sepsis definition, severity, and type of infection.
METHODS: For this meta-analysis focusing on procalcitonin-guided antibiotic management in critically ill patients with sepsis of any type, in February 2018 we updated the database of a previous individual patient data meta-analysis which was limited to patients with respiratory infections only. We used individual patient data from 11 trials that randomly assigned patients to receive antibiotics based on procalcitonin levels (the "procalcitonin-guided" group) or the current standard of care (the "controls"). The primary endpoint was mortality within 30 days. Secondary endpoints were duration of antibiotic treatment and length of stay.
RESULTS: Mortality in the 2252 procalcitonin-guided patients was significantly lower compared with the 2230 control group patients (21.1% vs 23.7%; adjusted odds ratio 0.89, 95% confidence interval (CI) 0.8 to 0.99; p = 0.03). These effects on mortality persisted in a subgroup of patients meeting the sepsis 3 definition and based on the severity of sepsis (assessed on the basis of the Sequential Organ Failure Assessment (SOFA) score, occurrence of septic shock or renal failure, and need for vasopressor or ventilatory support) and on the type of infection (respiratory, urinary tract, abdominal, skin, or central nervous system), with interaction for each analysis being > 0.05. Procalcitonin guidance also facilitated earlier discontinuation of antibiotics, with a reduction in treatment duration (9.3 vs 10.4 days; adjusted coefficient -1.19 days, 95% CI -1.73 to -0.66; p < 0.001).
CONCLUSION: Procalcitonin-guided antibiotic treatment in ICU patients with infection and sepsis patients results in improved survival and lower antibiotic treatment duration.
参考来源
- Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018. PMID: 30111341. doi:10.1186/s13054-018-2125-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。